An audiology or hearing aid center typically sells for 2.5x–4.5x Seller's Discretionary Earnings (SDE), or 0.5x–1.0x annual revenue, with clinically diversified multi-provider practices commanding the premium end and single-provider, hearing-aid-centric operations at the lower end. The U.S. audiology market includes approximately 15,000 private practices generating over $10 billion in combined revenue from hearing aid sales, diagnostic testing, tinnitus and balance services, and cochlear implant programming. The market is undergoing significant transformation as OTC hearing aids reshape the competitive landscape, PE-backed hearing healthcare platforms consolidate private practices, and manufacturer-owned retail networks expand.

Seller's Discretionary Earnings — the owner-audiologist's total economic benefit including salary, benefits, and add-backs — is the standard valuation method for audiology practices. In this industry, the owner's clinical production typically generates a significant portion of practice revenue, and the SDE calculation must carefully separate the owner's clinical labor value from the business's independent earning capacity. Common add-backs include the owner's salary, benefits, continuing education, professional memberships, and vehicle expenses. Practices trade between 2.5x and 4.5x SDE, with the range driven by clinical service diversification, provider count, recurring revenue percentage, referral source diversity, and OTC resilience. A practice at 2.5x is a single-provider operation generating 80%+ from hearing aid sales with no recurring revenue and heavy owner-clinical dependency. A practice at 4.5x has two or more audiologists, generates 40%+ from clinical services, maintains active service plans with 200+ patients, receives referrals from diversified sources, and has a demonstrated strategy for competing with OTC alternatives.

Revenue multiples for audiology practices fall between 0.5x and 1.0x, reflecting the professional services margin profile. Net margins typically range from 15% to 30% depending on product mix, provider compensation structure, and operational efficiency. Revenue multiples should be interpreted in the context of hearing aid revenue versus clinical service revenue — clinical service revenue is valued at a premium because it is not subject to OTC price competition.

For larger audiology operations generating $500K or more in annual EBITDA — typically multi-location practices with multiple providers — institutional buyers use EBITDA multiples in the 5x to 9x range. PE-backed hearing healthcare platforms (Hearing Life, Amplifon, Connect Hearing) are the most active institutional buyers, building national networks through serial acquisition. Hearing aid manufacturers acquire practices to control the distribution channel. ENT practice groups acquire audiology for integrated service capability. Hospital systems build audiology departments through private practice acquisition.

The unique valuation factor in audiology is the OTC disruption dynamic that is fundamentally repricing the industry. Before OTC hearing aids became available in 2022, the audiology business model was straightforward: patients needed a prescription, an audiologist dispensed the hearing aid, and the practice earned a margin of $1,000–$2,000 per device. OTC products have disrupted this model for the mild-to-moderate hearing loss segment — the largest segment by volume — by allowing consumers to purchase amplification devices without an audiologist. This doesn't eliminate the audiology practice's value, but it forces a strategic pivot from product-centric to service-centric revenue. The practices commanding premium multiples in the post-OTC environment have made this pivot explicitly: they emphasize diagnostic audiology (comprehensive hearing evaluations, tinnitus assessment, balance testing), clinical services that OTC cannot replicate (real-ear measurement verification, live speech mapping, cochlear implant programming), and ongoing care relationships (annual service plans, hearing rehabilitation programs). The critical metric buyers now evaluate is the practice's revenue breakdown between product sales and clinical services. A practice where 50% of revenue comes from non-product clinical services has a defensible business model regardless of OTC market evolution. One where 90% comes from hearing aid margins is at risk of revenue compression as OTC products improve and consumer awareness grows. For owners preparing to sell, building clinical service diversification is the single most impactful pre-sale investment because it simultaneously improves current valuation and reduces the OTC risk discount that buyers are now applying to product-heavy practices.

The audiology M&A market remains active despite — and partly because of — OTC disruption. PE-backed platforms acquire clinically sophisticated practices that can thrive in the evolving landscape. Manufacturer-owned networks acquire for distribution control. ENT groups and hospital systems acquire for service integration. For practices with clinical diversification, multiple providers, and demonstrated OTC resilience, the market offers competitive multiples. Product-centric single-provider practices face a challenging environment and should invest in clinical service development before pursuing a sale.

Use our free calculator above to get your instant estimate, then track your value monthly with YourExitValue.